Preview

Rational Pharmacotherapy in Cardiology

Advanced search

PHARMACOECONOMIC ANALYSIS OF CARVEDILOL THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC RISK FACTORS (ACCORDING TO THE CAMELLIA STUDY)

https://doi.org/10.20996/1819-6446-2010-6-4-485-490

Full Text:

Abstract

Aim. To perform cost-effectiveness analysis of 24 weeks antihypertensive therapy based on carvedilol or metoprolol in patients with arterial hypertension (HT) 1-2 degrees and overweight/obesity. To assess effects of carvedilol therapy on 10-year expected risk of cardiovascular complications (CVC).

Material and methods. Patients with HT and overweight/obesity (n=320) were included into the study and randomly split in two groups. Patients of the first group (n=160) received carvedilol as a basic therapy and patients of the second group (n=160) — metoprolol. Both groups of the patients were comparable on key clinical characteristics.

Results. In 24 weeks of treatment systolic and diastolic blood pressure (BP) decreased significantly in comparison with the baseline level (p<0.0001). Dose doubling of beta-blockers was required more often in patients treated with carvedilol. At the same time a combined antihypertensive therapy of the patients treated with carvedilol was required less (p>0.05). Target BP levels were achieved in carvedilol and metoprolol groups in 96.2and 95.5% of patients respectively (p=0.85). Carvedilol had better effect on plasma metabolic indicators such as glucose (p<0.01), lipid profile, uric acid level. Reduction in expected 10-year risk of death was more pronounced in 24 weeks carvedilol treatment. Cost of target BP level achievement was approximately 2.5 times higher in carvedilol group than this in metoprolol group. However cost of additional therapy was higher in metoprolol group. 1% reduction of the 10-year expected risk of CVC death cost 1 847 rubles in carvedilol therapy.

Conclusion. Carvedilol therapy (vs metoprolol one) has a higher cost under comparable efficacy. Additional expenses are compensated with the favorable effect on metabolic indices and a more pronounced effect on reduction in the 10-year expected risk of CCO death. That is why carvedilol can be recommended to patients with HT and metabolic risk factors. Longer studies are necessary to assess an effect of carvedilol therapy on prognosis in patients with HT and concomitant metabolic disorders.

About the Authors

S. Y. Martsevich
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


N. P. Kutishenko
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


A. D. Deev
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


S. A. Shalnova
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


R. G. Oganov
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


References

1. Ягудина Р.И., Куликов А.Ю. Фармакоэкономика: общие сведения, методы исследования. Новая аптека 2007; 9: 73-78.

2. Booth N., Jula A., Aronen P. et al. Cost-effectiveness analysis of guidelines for antihypertensive care in Finland. BMC Health Serv Res 2007;7:172.

3. Elliott W.J. The costs of treating hypertension: what are the long-term realities of cost containment and pharmacoeconomics? Postgrad Med 1996;99(4):241-8, 251-2.

4. Гиляревский С.Р., Орлов В.А. Использование анализа эффективности лечения для принятия клинического решения в кардиологии. Кардиология 1997; 9: 70-80.

5. Ягудина Р.И.,КуликовА.Ю.,Крысанов И.С. и др. Особенности методологии фармакоэкономических исследований в условиях здравоохранения Российской Федерации (обзор публикаций за период с 1995 по 2007 гг.). Фармакоэкономика 2009; 1: 3-6.

6. Sancho L.G. Reviewing the literature of cost-effectiveness and cost-utility analysis in health. Cad Saude Publica 2008;24(12):2735-46.

7. Воробьев П.А., Авксентьева М.В., Юрьев А.С., Сура М.В. Клинико-экономический анализ (оценка, выбор медицинских технологий и управление качеством медицинской помощи). М.: «Ньюдиамед»; 2004.

8. Марцевич С.Ю., Кутишенко Н.П. от имени рабочей группы исследования КАМЕЛИЯ. Исследование КАМЕЛИЯ: сравнение терапии, основанной на карведилоле или метопрололе у больных артериальной гипертонией и избыточной массой тела/ожирением. Рациональная Фармакотерапия в Кардиологии 2008;4(5):34-8.

9. Марцевич С.Ю., Кутишенко Н.П., Шилова Е.В. и др. Сравнение терапии, основанной на карведилоле или метопрололе, у больных артериальной гипертонией и избыточной массой тела/ожирением. Первые результаты исследования КАМЕЛИЯ. Рациональная Фармакотерапия в Кардиологии 2009; 5(1):23-27.

10. Марцевич С.Ю., Кутишенко Н.П., Шилова Е.В. и др. Сравнение метаболических эффектов карведилола и метопролола у пациентов с артериальной гипертонией и избыточной массой тела/ожирением. Исследование КАМЕЛИЯ. Рациональная Фармакотерапия вКардиологии2009; 5(2):33-38.

11. Марцевич С.Ю., Кутишенко Н.П., Деев А.Д., Шальнова С.А. и др. Исследование «КАМЕЛИЯ». Научная значимость и рекомендации для практического врача. Рациональная Фармакотерапия в Кардиологии 2009; 5(4): 7-8.

12. www.AptekaMos.ru

13. Захаревич О.А., Леонова М.В., Белоусов Ю.Б. Анализ минимизации затрат и «затраты-эффективность» для лечения больных мягкой и умеренной артериальной гипертонией. Бюллетень клинико-экономического анализа 2001; 2: 47-51.

14. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6): 1105-87.

15. Диагностика и лечение артериальной гипертензии. Оганов Р.Г., Мамедов М.Н., редакторы. Национальные клинические рекомендации. М.: МЕДИ Экспо;2009. С. 7-37.

16. Packer M., Coats A.J., Flowler M.B. et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344(22):1651-1658.

17. Poole-Wilson P.A., Swedberg K., Cleland J.G. et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362(9377): 7-14.

18. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357(9266): 1385-90.

19. Remme W.J., Riegger G., Hildebrandt P. et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 2004;18(1):57-66.

20. Elliott W.J., Mayer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet 2007; 369(9557): 201-207.

21. Bakris G.L., Fonseca V., Katholi R.E. et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.JAMA 2004;292(18):2227- 2236.

22. Остроумова О.Д., Недогода С.В., Мамаев В.И., Ищенко К.А. Дифференцированный подход к терапии артериальной гипертонии с учетом фармакоэкономики: возможности иАПФ. Качественная клиническая практика 2003; 1: 38-45.

23. Finkelstein E.A., Troped P.J., Will J.C., Palombo R. Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: the Massachusetts WISEWOMAN project. J Womens Health Gend Based Med 2002;11(6):519-26.

24. Finkelstein E.A., Khavjou O., Will J.C. Cost-effectiveness of WISEWOMAN, a Program Aimed at Reducing Heart Disease Risk among Low-Income Women. J Womens Health (Larchmt) 2006;15(4): 379-89.


For citation:


Martsevich S.Y., Kutishenko N.P., Deev A.D., Shalnova S.A., Oganov R.G. PHARMACOECONOMIC ANALYSIS OF CARVEDILOL THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC RISK FACTORS (ACCORDING TO THE CAMELLIA STUDY). Rational Pharmacotherapy in Cardiology. 2010;6(4):485-490. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-4-485-490

Views: 419


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)